All news

Novo's CagriSema shows 25% weight loss in women

CNBC · RSS · · AI-summarised by FinFlash

Novo Nordisk released new evidence that its experimental CagriSema injection can improve upon the weight loss achieved with Wegovy, its blockbuster GLP-1 obesity injection. A late-stage analysis showed 25% weight loss in women. The data supports Novo's effort to defend its obesity franchise as competition in the GLP-1 market intensifies, a key factor for investors weighing the company's growth pipeline.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.